Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836619 | 1.00 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL30987621 | 1.00 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL2380961 | 1.00 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL14915162 | 0.89 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL21845196 | 0.89 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL14915166 | 0.89 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL14915165 | 0.89 | PTPN1 (0.49) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL31239774 | 0.87 | PTPN1 (0.48) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL31000507 | 0.86 | PTPN1 (0.47) | PTPN1NR1H2NR1H3MMP2ANPEP | |
| SCHEMBL29851000 | 0.86 | PTPN1 (0.47) | PTPN1NR1H2NR1H3MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404030-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3154985-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, MAVS | PTPN1 2134/4885NR1H2 1821/4885NR1H3 1230/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PTPN1 3735/4885NR1H2 2935/4885NR1H3 2641/4885 |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PTPN1 3735/4885NR1H2 2935/4885NR1H3 2641/4885 |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PTPN1 3735/4885NR1H2 2935/4885NR1H3 2641/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | PTPN1 3735/4885NR1H2 2935/4885NR1H3 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.